PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

The association between RARβ and FHIT promoter methylation and the carcinogenesis of patients with cervical carcinoma: A meta-analysis.

Abstract The RARβ and FHIT promoter methylation are observed in some cervical carcinoma. However, the association between RARβ and FHIT promoter methylation and cervical carcinogenesis remains unclear. This study was carried out to evaluate the correlation between RARβ or FHIT promoter methylation and cervical carcinogenesis. Eligible publications were searched via online databases. The combined odds ratios and corresponding 95% confidence intervals were calculated and summarized. In all, 17 eligible articles on RARβ and FHIT promoter methylation were identified in the study. RARβ promoter methylation was significantly higher in cervical cancer than in cervical intraepithelial neoplasia lesions and normal cervical tissues (odds ratio = 3.90, p = 0.018; odds ratio = 12.98, p < 0.001, respectively). There was more FHIT promoter methylation in cervical cancer than in cervical intraepithelial neoplasia lesions and normal controls (odds ratio = 8.0, p = 0.055; odds ratio = 10.75, p < 0.001, respectively). In addition, FHIT promoter methylation was correlated with clinical stage (advanced stage vs early stage: odds ratio = 2.69, p = 0.056) and tumor grade (high grade vs low grade: odds ratio = 4.11, p < 0.001). RARβ and FHIT promoter methylation may be associated with the carcinogenesis of cervical cancer. FHIT promoter methylation may play a crucial role in cervical cancer progression. Additional studies with large sample sizes are essential to confirm our findings.
PMID
Related Publications

Association of the promoter methylation and protein expression of Fragile Histidine Triad (FHIT) gene with the progression of differentiated thyroid carcinoma.

Folate deficiency and FHIT hypermethylation and HPV 16 infection promote cervical cancerization.

Effect of aberrant promoter methylation of FHIT and RASSF1A genes on susceptibility to cervical cancer in a North Indian population.

Combined effects methylation of FHIT, RASSF1A and RARβ genes on non-small cell lung cancer in the Chinese population.

Promoter methylation of DAPK1, FHIT, MGMT, and CDKN2A genes in cervical carcinoma.

Authors

Mayor MeshTerms
Keywords

FHIT

RARβ

cervical cancer

cervical intraepithelial neoplasia lesions

clinical features

methylation

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28639889
OWN - NLM
STAT- MEDLINE
DA  - 20170622
DCOM- 20170711
LR  - 20170713
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 6
DP  - 2017 Jun
TI  - The association between RARbeta and FHIT promoter methylation and the
      carcinogenesis of patients with cervical carcinoma: A meta-analysis.
PG  - 1010428317709126
LID - 10.1177/1010428317709126 [doi]
AB  - The RARbeta and FHIT promoter methylation are observed in some cervical
      carcinoma. However, the association between RARbeta and FHIT promoter methylation
      and cervical carcinogenesis remains unclear. This study was carried out to
      evaluate the correlation between RARbeta or FHIT promoter methylation and
      cervical carcinogenesis. Eligible publications were searched via online
      databases. The combined odds ratios and corresponding 95% confidence intervals
      were calculated and summarized. In all, 17 eligible articles on RARbeta and FHIT 
      promoter methylation were identified in the study. RARbeta promoter methylation
      was significantly higher in cervical cancer than in cervical intraepithelial
      neoplasia lesions and normal cervical tissues (odds ratio = 3.90, p = 0.018; odds
      ratio = 12.98, p &lt; 0.001, respectively). There was more FHIT promoter methylation
      in cervical cancer than in cervical intraepithelial neoplasia lesions and normal 
      controls (odds ratio = 8.0, p = 0.055; odds ratio = 10.75, p &lt; 0.001,
      respectively). In addition, FHIT promoter methylation was correlated with
      clinical stage (advanced stage vs early stage: odds ratio = 2.69, p = 0.056) and 
      tumor grade (high grade vs low grade: odds ratio = 4.11, p &lt; 0.001). RARbeta and 
      FHIT promoter methylation may be associated with the carcinogenesis of cervical
      cancer. FHIT promoter methylation may play a crucial role in cervical cancer
      progression. Additional studies with large sample sizes are essential to confirm 
      our findings.
FAU - Shu, Ruming
AU  - Shu R
AD  - Department of Gynaecology and Obstetrics, The Third Affiliated Hospital of
      Nanchang University, Nanchang, China.
FAU - He, Jie
AU  - He J
AD  - Department of Gynaecology and Obstetrics, The Third Affiliated Hospital of
      Nanchang University, Nanchang, China.
FAU - Wu, Chengzhen
AU  - Wu C
AD  - Department of Gynaecology and Obstetrics, The Third Affiliated Hospital of
      Nanchang University, Nanchang, China.
FAU - Gao, Jun
AU  - Gao J
AD  - Department of Gynaecology and Obstetrics, The Third Affiliated Hospital of
      Nanchang University, Nanchang, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Receptors, Retinoic Acid)
RN  - 0 (fragile histidine triad protein)
RN  - 0 (retinoic acid receptor beta)
RN  - EC 3.6.- (Acid Anhydride Hydrolases)
SB  - IM
MH  - Acid Anhydride Hydrolases/*genetics
MH  - Carcinogenesis/genetics
MH  - Cervical Intraepithelial Neoplasia
MH  - DNA Methylation/*genetics
MH  - Disease Progression
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Neoplasm Proteins/*genetics
MH  - Promoter Regions, Genetic
MH  - Receptors, Retinoic Acid/*genetics
MH  - Uterine Cervical Neoplasms/*genetics/pathology
OTO - NOTNLM
OT  - FHIT
OT  - RARbeta
OT  - cervical cancer
OT  - cervical intraepithelial neoplasia lesions
OT  - clinical features
OT  - methylation
EDAT- 2017/06/24 06:00
MHDA- 2017/07/14 06:00
CRDT- 2017/06/23 06:00
AID - 10.1177/1010428317709126 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Jun;39(6):1010428317709126. doi: 10.1177/1010428317709126.